Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Kopran Ltd

KOPRAN

Kopran Ltd

KOPRAN
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,020 cr, stock is ranked 1,483
High RiskStock is 3.76x as volatile as Nifty
212.373.13% (+6.44)
212.373.13% (+6.44)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,020 cr, stock is ranked 1,483
High RiskStock is 3.76x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,020 cr, stock is ranked 1,483
High RiskStock is 3.76x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
19.292.081.42%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.536.560.52%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Kopran Limited is engaged in pharmaceutical business. The Company's business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 11.75%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.16% to 0.17%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 16.23%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue298.71320.50322.92360.96360.13509.80488.12554.06629.20651.72
Raw Materialssubtract181.44180.85193.05217.24232.83286.27300.57345.95400.88557.82
Power & Fuel Costsubtract14.1013.7114.9017.1018.0816.6519.2723.1624.52
Employee Costsubtract28.0231.3732.2437.1136.8537.1643.2749.9552.28
Selling & Administrative Expensessubtract25.0325.3928.1727.8829.6034.2435.7535.3737.00
Operating & Other expensessubtract18.7122.3914.5612.24-4.0035.71-8.7344.7725.50
Depreciation/Amortizationsubtract8.128.338.518.749.5810.1911.1012.7112.8914.58
Interest & Other Itemssubtract12.5613.708.608.998.916.245.126.088.599.24
Taxes & Other Itemssubtract0.004.852.407.647.2721.7320.758.8316.5917.17
EPS2.544.604.745.554.8614.2413.345.6510.5710.97
DPS0.000.000.000.000.003.003.003.003.003.00
Payout ratio0.000.000.000.000.000.210.220.530.280.27
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2016

Annual report

PDF
FY 2017

Annual report

PDF
FY 2018

Annual report

PDF
FY 2019

Annual report

PDF
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF

Investor Presentation

Jun 11PDF
Feb 4PDF
Nov 6PDF
FY 2022

Annual report

PDF

Investor Presentation

May 31PDF
Nov 4PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Kopran Ltd20.032.081.42%
Sun Pharmaceutical Industries Ltd45.356.470.75%
Cipla Ltd28.514.380.89%
Torrent Pharmaceuticals Ltd68.4516.540.84%

Price Comparison

Compare KOPRAN with any stock or ETF
Compare KOPRAN with any stock or ETF
KOPRAN
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.21%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding44.49%0.00%0.22%1.32%53.97%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.34%0.39%0.48%0.84%0.68%1.32%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 1 Mutual Funds holding Kopran Ltd

Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0008%0.05%0.05%95/102 (-10)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 2, 2024

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Sep 2, 2024

Cash Dividend

Ex DateEx DateSep 7, 2023

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Sep 7, 2023

Cash Dividend

Ex DateEx DateAug 4, 2022

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Aug 4, 2022

Cash Dividend

Ex DateEx DateAug 5, 2021

Final
Final | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Aug 5, 2021

Cash Dividend

Ex DateEx DateNov 5, 2020

Interim
Interim | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Nov 5, 2020

News & Opinions
Earnings
Kopran consolidated net profit declines 46.41% in the September 2024 quarter

Net profit of Kopran declined 46.41% to Rs 7.38 crore in the quarter ended September 2024 as against Rs 13.77 crore during the previous quarter ended September 2023. Sales declined 0.68% to Rs 151.56 crore in the quarter ended September 2024 as against Rs 152.59 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales151.56152.59 -1 OPM %9.7214.96 - PBDT13.5021.02 -36 PBT9.6418.25 -47 NP7.3813.77 -46 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Kopran to discuss results

Kopran will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Kopran schedules AGM

Kopran announced that the Annual General Meeting (AGM) of the company will be held on 11 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Kopran consolidated net profit rises 300.72% in the June 2024 quarter

Net profit of Kopran rose 300.72% to Rs 11.10 crore in the quarter ended June 2024 as against Rs 2.77 crore during the previous quarter ended June 2023. Sales rose 19.18% to Rs 139.44 crore in the quarter ended June 2024 as against Rs 117.00 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales139.44117.00 19 OPM %13.025.39 - PBDT18.616.87 171 PBT14.733.61 308 NP11.102.77 301 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Kopran receives environmental clearance for GoI for manufacturing of APIs at Panoli unit

Kopran has received Environmental Clearance from Government of India ' Ministry of Environment, Forest and Climate Change on 30 July 2024 for manufacturing of synthetic organic chemicals (Active Pharmaceutical Ingredients and its Intermediates) up to 97 MTs/Month at its Manufacturing Unit at Plot no. 663, GIDC Panoli, Taluka: Ankleshwar, District: Bharuch, Gujarat. The Company will now obtain Consent to Establish (CTE) and Consent to Operate (CCA) from Gujarat Pollution Control Board for additional capacities approval under the Environmental Clearance received.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Kopran schedules board meeting

Kopran will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Stock market update: Stocks that hit 52-week highs on NSE in today’s trade

1 year agoEconomic Times

Creative Eye Ltd leads gainers in ‘B’ group

1 year agoBusiness Standard

SVP Global Textiles Ltd leads losers in ‘B’ group

1 year agoBusiness Standard

Chemcon Speciality Chemicals Ltd leads losers in ‘B’ group

2 years agoBusiness Standard